Cellular Immune Responses in the Liver in Chronic Hepatitis C (CHC) Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01062659 |
Recruitment Status
:
Withdrawn
(Lack of funding)
First Posted
: February 4, 2010
Last Update Posted
: April 1, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Hepatitis C, Chronic Liver Diseases Virus Diseases |
Study Type : | Observational |
Actual Enrollment : | 0 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Characterization of Cellular Immune Responses in the Liver in Patients With Chronic Hepatitis C Virus Infection |
Study Start Date : | February 2010 |
Estimated Primary Completion Date : | December 2012 |
Estimated Study Completion Date : | March 2013 |
Group/Cohort |
---|
chronic Hepatitis C
Patients with chronic Hepatitis C (CHC) Genotype 1-4 who are naive to antiviral treatment
|

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- proven chronic hepatitis C
- aged between 18 and 65
- willingness to give written informed consent to the study protocol
Exclusion Criteria:
- history of having received any IFN, PEG-IFN or RBV
- not eligible for antiviral treatment with peginterferon and ribavirin by standard of care

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01062659
Germany | |
University Hospital Ulm | |
Ulm, Germany |
Principal Investigator: | Dietmar M Klass, MD | University of Ulm |
Responsible Party: | Dietmar M. Klass, Dr. med., University of Ulm |
ClinicalTrials.gov Identifier: | NCT01062659 History of Changes |
Other Study ID Numbers: |
TCell |
First Posted: | February 4, 2010 Key Record Dates |
Last Update Posted: | April 1, 2014 |
Last Verified: | March 2014 |
Keywords provided by Dietmar M. Klass, University of Ulm:
HCV hepatitis C virus CHC chronic hepatitis c interferon |
ribavirin Hepatitis, Viral, Human Anti-Infective Agents peginterferon alfa-2a peginterferon alfa-2b |
Additional relevant MeSH terms:
Hepatitis Hepatitis A Hepatitis C Hepatitis, Chronic Hepatitis C, Chronic Liver Diseases Virus Diseases |
Digestive System Diseases Hepatitis, Viral, Human Enterovirus Infections Picornaviridae Infections RNA Virus Infections Flaviviridae Infections |